Skip to main content
All lobbying filings

U.S. PUBLIC INTEREST RESEARCH GROUP

Lobbying for U.S. PUBLIC INTEREST RESEARCH GROUP

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 17, 2026
Expenses
$10,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 3
  • Food & Drug Administration (FDA)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 2
 Lobbying activity 3
Health Issues

In support of S.2355/H.R.5582 Patients Deserve Price Tags Act, in support of health care price transparency; Generic Drug User Fee Amendments (GDUFA); Prescription Drug User Fee Act (PDUFA)

Banking

Support for the Close the Shadow Banking Loophole Act, which would close an exemption that is being used by commercial, retail, and tech businesses to get the benefits of being an FDIC-backed bank without federal requirements.

Financial Institutions/Investments/Securities

Support for the Credit Card Competition Act in the House and Senate, to foster competition in the credit card processing marketplace. Calling on Congress to restore full funding for the CFPB.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem